FDA rules on e-cigarettes; Gilead inks deal with MicroDose;

> The FDA has decided to back off its previous stance and regulate e-cigarettes as tobacco products, rather than under stricter rules for drug-delivery devices. Story

> A condom aimed at helping men maintain erections while wearing it (thus, encouraging men to wear condoms) does its magic by delivering the drug in a formulation that does not weaken the condom and immobilizes the drug in the lubricant so it only affects the wearer, according to the Wall Street Journal's Health Blog. Story

> Gilead has entered into a license and collaboration agreement with drug delivery specialists MicroDose Therapeutx to develop a treatment for respiratory syncytial virus. Story

> Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach? Abstract

> Drug delivery patent application of the week: Nanogels for cellular delivery of therapeutics Patent application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.